Patent · US Active

Parenteral formulations

US11229612B2 · kind B2 · utility

25Cited by

23References

16Claims

0Family size

Assignee

GW Research Limited · GB

Inventors

Stephen Wayne Wright · Old Lyme, US
Jitinder WILKHU · Cambridge, GB

Key dates

Filing date	Jun 29, 2017
Grant date	Jan 25, 2022
Priority date	—
Expiry date	Jun 29, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K47/26
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerolpropyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.